
Ruth Van Daele

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6392664/publications.pdf Version: 2024-02-01



Ρυτή Νλη Πλειε

#	Article	IF	CITATIONS
1	Isavuconazole in the Treatment of Aspergillus fumigatus Fracture-Related Infection: Case Report and Literature Review. Antibiotics, 2022, 11, 344.	1.5	3
2	Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSAâ€FLU study. Mycoses, 2022, 65, 656-660.	1.8	3
3	Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. Mycoses, 2021, 64, 1111-1116.	1.8	3
4	Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically III Patients with Pneumonia: An Observational Cohort Study. Antibiotics, 2021, 10, 557.	1.5	9
5	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Medicine, 2021, 47, 674-686.	3.9	49
6	Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	1
7	A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. Microorganisms, 2021, 9, 1543.	1.6	23
8	A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication. Therapeutic Drug Monitoring, 2021, 43, 512-518.	1.0	9
9	Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid. Antibiotics, 2021, 10, 1112.	1.5	5
10	Letermovir exposure in transplant patients with end-stage renal disease on renal replacement therapy. Journal of Antimicrobial Chemotherapy, 2021, 76, 3322-3325.	1.3	2
11	Interaction between flucloxacillin and azoles: is isavuconazole next?. Mycoses, 2021, 64, 1508-1511.	1.8	3
12	Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. Journal of Antimicrobial Chemotherapy, 2021, 76, 1234-1241.	1.3	14
13	Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically III Patients. Microorganisms, 2021, 9, 2068.	1.6	8
14	Ultra-performance liquid chromatography for quantification of amphotericin B plasma concentrations after use of liposomal amphotericin B. Journal of Antimicrobial Chemotherapy, 2021, 76, 961-966.	1.3	2
15	Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 539-550.	1.5	12
16	Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?. Frontiers in Pharmacology, 2020, 11, 620.	1.6	62
17	Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B. Medical Mycology, 2020, 58, 874-880.	0.3	8
18	Development and External Validation of an Online Clinical Prediction Model for Augmented Renal Clearance in Adult Mixed Critically III Patients: The Augmented Renal Clearance Predictor. Critical Care Medicine, 2020, 48, e1260-e1268.	0.4	14

#	Article	IF	CITATIONS
19	Antifungal drugs: What brings the future?. Medical Mycology, 2019, 57, S328-S343.	0.3	141
20	Diagnosing Invasive Mold Infections: What Is Next. Current Fungal Infection Reports, 2018, 12, 161-169.	0.9	7